DelveInsight’s, “H3N2 Infection Pipeline Insight, 2025,” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in H3N2 Infection pipeline landscape. It covers the H3N2 Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the H3N2 Infection pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in H3N2 Infection Research. Learn more about our innovative pipeline today! @ H3N2 Infection Pipeline Outlook
Key Takeaways from the H3N2 Infection Pipeline Report
- In July 2025, Seqirus announced a Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV) in adults ≥65 years of age. The aim of the study is to evaluate MF59-adjuvanted influenza vaccine compared with non-adjuvanted influenza vaccine in the prevention of reverse transcription-polymerase chain reaction (RT-PCR)-confirmed influenza A and/or B in subjects ≥65 years of age.
- DelveInsight’s H3N2 Infection pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for H3N2 Infection treatment.
- The leading H3N2 Infection Companies such as Novartis Vaccines, PDS Biotechnology Corporation, Sanofi, Moderna Therapeutics, Pfizer, Cidara Therapeutics, GRDG Sciences, FluGen Inc., Barinthus Biotherapeutics and others.
- Promising H3N2 Infection Pipeline Therapies such as H3N2 (A/Belgium/2417/2015), Saline, MVA-NP+M1, PrEP-001 and others.
Stay informed about the cutting-edge advancements in H3N2 Infection treatments. Download for updates and be a part of the revolution in Infectious Disease Care @ H3N2 Infection Clinical Trials Assessment
H3N2 Infection Emerging Drugs Profile
- mRNA-1083: Moderna Therapeutics
mRNA-1083 is under development for the prevention of influenza virus infection caused by influenza A/H1N1, A/H3N2, and influenza B/Yamagata and B/Victoria strains and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in 18 to 79 years of age group. It is a combination vaccine of mRNA-1283, which encodes Receptor Binding Doman (RBD) and N-Terminal Domain (NTD) of the spike protein and mRNA-1010, which encodes hemagglutinin (HA) glycoproteins of influenza A/H1N1, A/H3N2, and influenza B/Yamagata and B/Victoria-lineages. It is administered through intramuscular route in the form of sterile liquid for injection. Currently, the drug is in Phase III stage of its clinical trial for the treatment H3N2 infection.
- CD-388: Cidara therapeutics
CD-388 is under development of the treatment and prevention of influenza virus A, seasonal influenza, pandemic influenza and influenza virus B infections. The drug candidate is a second generation, anti-viral Fc conjugate (AVC). It comprises of two moieties attached through a chemical linker. One is a targeting moiety (TM) that recognizes cell surface target and another is an effector moiety (EM) that is recognized by the immune system. It is administered through intramuscular and subcutaneous route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of H3N2 infection.
- PF-07845104: Pfizer
PF-07845104 is a prophylactic saRNA Vaccine developed by Pfizer. Its therapeutics area include infectious respiratory diseases. Currently, the drug is in phase I stage of its clinical trial for the treatment of H3N2 infection.
The H3N2 Infection Pipeline Report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of H3N2 Infection with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for H3N2 Infection Treatment.
- H3N2 Infection Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- H3N2 Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the H3N2 Infection market.
Learn more about H3N2 Infection Drugs opportunities in our groundbreaking H3N2 Infection research and development projects @ H3N2 Infection Unmet Needs
H3N2 Infection Companies
Novartis Vaccines, PDS Biotechnology Corporation, Sanofi, Moderna Therapeutics, Pfizer, Cidara Therapeutics, GRDG Sciences, FluGen Inc., Barinthus Biotherapeutics and others.
H3N2 Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
H3N2 Infection Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Discover the latest advancements in H3N2 Infection treatment by visiting our website. Stay informed about how we're transforming the future of Infectious Disease @ H3N2 Infection Market Drivers and Barriers, and Future Perspectives
Scope of the H3N2 Infection Pipeline Report
- Coverage- Global
- H3N2 Infection Companies- Novartis Vaccines, PDS Biotechnology Corporation, Sanofi, Moderna Therapeutics, Pfizer, Cidara Therapeutics, GRDG Sciences, FluGen Inc., Barinthus Biotherapeutics and others.
- H3N2 Infection Pipeline Therapies- H3N2 (A/Belgium/2417/2015), Saline, MVA-NP+M1, PrEP-001 and others.
- H3N2 Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- H3N2 Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of H3N2 Infection Pipeline on our website @ H3N2 Infection Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- H3N2 infection: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- H3N2 infection– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- mRNA-1083: Moderna Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- CD-388: Cidara therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- PF-07845104: Pfizer
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- H3N2 infection Key Companies
- H3N2 infection Key Products
- H3N2 infection- Unmet Needs
- H3N2 infection- Market Drivers and Barriers
- H3N2 infection- Future Perspectives and Conclusion
- H3N2 infection Analyst Views
- H3N2 infection Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/h3n2-infection-pipeline-insight
